Lysophospholipid mediators of immunity and neoplasia.

Mei‐Chuan Huang,M. Graeler,G. Shankar,J. Spencer,E. Goetzl

DOI: https://doi.org/10.1016/S1388-1981(02)00151-8

2002-05-23

Biochimica et Biophysica Acta

Abstract:

What problem does this paper attempt to address?

A comprehensive study of intravenous iron-carbohydrate nanomedicines: From synthesis methodology to physicochemical and pharmaceutical characterization

Ozra Tabasi,Roohi Razlighi,Cavus Falamaki,Mahdi Roohi Razlighi

DOI: https://doi.org/10.1080/07328303.2023.2272892

2023-11-02

Journal of Carbohydrate Chemistry

Abstract:Administration of intravenous iron is pivotal in the management of iron-deficiency anemia patients. In the past, parenteral iron was administrated as a ferric hydroxide complex that caused severe toxic reactions. The introduction of compounds containing iron in a core surrounded by a carbohydrate shell has circumvented this problem. Intravenous iron complexes, such as iron sucrose and iron carboxymaltose, consist of a polynuclear Fe (III)-oxyhydroxide/oxide core that is coated with a specific carbohydrate molecule. The carbohydrate shell stabilizes the insoluble iron core particles in colloidal suspension form and slows down the release of iron. Moreover, the carbohydrate shell chemistry differences influence the stability of the complex and iron release rate. In particular, this paper discusses the preparation method, physicochemical properties, and characteristics of iron sucrose, ferric derisomaltose, iron carboxymaltose, and ferumoxytol. These products differ in their physicochemical and clinical properties such as molecular weight distribution, particle size, zeta potential, free, and labile iron content, stability and release of iron in serum, and maximum tolerated dose. The first-generation of intravenous iron formulations were replaced with new intravenous iron dextran–free formulations, due to an elevated risk of anaphylactic reactions. Comparatively, the third-generation intravenous iron formulations, such as ferric derisomaltose, iron carboxymaltose, and ferumoxytol, allow higher doses of iron due to high complex stability and safety than the second generation formulations like iron sucrose.

biochemistry & molecular biology,chemistry, organic
Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations

A B Pai,D E Meyer,B C Bales,V E Cotero,M P Pai,N Zheng,W Jiang

DOI: https://doi.org/10.1111/cts.12443

Abstract:Emerging data from global markets outside the United States, where many generic iron sucrose formulations are available, have revealed that non-US generic intravenous (i.v.) iron formulations may have iron release profiles that differ from the reference listed drug (RLD). The first generic i.v. iron approved in the United States was sodium ferric gluconate complex in 2011. We evaluated chelatable and redox labile iron assay methods to measure the amount of labile iron released from i.v. iron formulations in biorelevant matrices in vitro. The majority of published labile iron assays evaluated were not suitable for use in vitro due to overwhelming interference by the presence of the i.v. iron products. However, an optimized high-performance liquid chromatography (HPLC)-based method performed well for use in vitro labile iron detection in a biorelevant matrix. Application of this method may enhance bioequivalence evaluation of generic i.v. iron formulations in the future.
An analytical method for the quantitative determination of iron ion chelating capacity: development and validation

Éverton da Silva Santos,Leticia de Melo Teixeira,Juliana Cristina Castro,Laura Paulino Mardigan,José Rivaldo dos Santos,José Eduardo Gonçalves,Arildo José Braz de Oliveira,Regina Aparecida Correia Gonçalves,Juliana Cristina Castro

DOI: https://doi.org/10.4025/actascibiolsci.v44i1.59739

2022-05-13

Abstract:Iron is a fundamental microelement for human life; however, deficiencies or excesses of these metal ions can cause severe complications and mortality. Chelators are compounds that bind and inhibit iron. Ultraviolet-visible (UV-vis) spectrophotometric methods are key analytical tools in the identification of chemical entities, with the benefits of having good precision and accuracy, and the equipment being easily available as well as quick and simple to implement. In this study, we aimed to provide an alternative, cheaper method for the quantification of iron ion chelation by substituting ferrozine for gallic acid and validating its use with UV-vis according to official ANVISA and ICH guidelines. The parameters assessed were specificity, linearity, precision, accuracy, robustness, and finally, the percentage of iron ions chelating was calculated. The results demonstrated that this method was accurate, simple, specific, selective, precise, and reproducible, and was successfully validated for the determination of iron ions chelating. The percentage of iron ions chelating, promoted by the standard chelator EDTA, was 45% and 47% for Fe2+ and Fe3+, respectively. It is concluded that this new method is beneficial in terms of its simplicity, rapidness, low cost, and the fact that it produces very low levels of dangerous residues.

English Else
ESI-MS quantitation of iron as its 4-(2-pyridylazo)resorcinol (PAR) complex: application to pharmaceutical tablets containing iron oxide pigment

Dendi Susanto,Ann M English,Ravi Sharma,Elizabeth Kwong

DOI: https://doi.org/10.1002/jms.1919

Abstract:Quantitation of iron oxide (Fe(2)O(3)) in pharmaceutical formulations using electrospray ionization mass spectrometry (ESI-MS) following iron complexation with 4-(2-pyridylazo)resorcinol (PAR) was evaluated. Complexation of Fe(III) with PAR was found to produce an intense mass spectral signal at low pH compared to the free ligand. Using the selected-ion-monitoring mode of a triple-quadrupole mass spectrometer, the signal at m/z 484 arising from the singly charged [Fe(III)(PAR)(2)](+) complex gave a limit of detection of ~2 µM for total iron. The linear range of the calibration curve was found to be 2-43 µM total iron. Trace iron interference was decreased to submicromolar levels by performing an optimized labware cleaning protocol and instrument replumbing using Polyetheretherketone (PEEK) tubing. The validation parameters of this ESI-MS total iron analysis (specificity, linearity, precision, accuracy, robustness and stability) are within the acceptance criteria listed in the validation guidelines developed by the Food and Drug Administration for industry. Recovery of 93% of the added iron indicated a satisfactory extraction procedure for tablets containing Fe(2)O(3) pigment. There was no statistical difference between the results obtained by ESI-MS and the common elemental method, inductively coupled plasma-optical emission spectroscopy. Since the proposed ESI-MS method can be performed on a mass spectrometer equipped with an ESI source, which is standard instrumentation in the pharmaceutical industry, the method validated here provides an alternate method for metal ion analysis by ESI-MS.
A Friendly Complexing Agent for Spectrophotometric Determination of Total Iron

Valeria M Nurchi,Rosita Cappai,Nadia Spano,Gavino Sanna

DOI: https://doi.org/10.3390/molecules26113071

IF: 4.6

2021-05-21

Molecules

Abstract:Iron, one of the most common metals in the environment, plays a fundamental role in many biological as well as biogeochemical processes, which determine its availability in different oxidation states. Its relevance in environmental and industrial chemistry, human physiology, and many other fields has made it necessary to develop and optimize analysis techniques for accurate determination. Spectrophotometric methods are the most frequently applied in the analytical determination of iron in real samples. Taking advantage of the fact that desferrioxamine B, a trihydroxamic acid used since the 1970s in chelation therapy for iron overload treatment, forms a single stable 1:1 complex with iron in whichever oxidation state it can be found, a smart spectrophotometric method for the analytical determination of iron concentration was developed. In particular, the full compliance with the Lambert-Beer law, the range of iron concentration, the influence of pH, and the interference of other metal ions have been taken into account. The proposed method was validated in terms of LoD, LoQ, linearity, precision, and trueness, and has been applied for total iron determination in natural water certified material and in biological reference materials such as control human urine and control serum.
Ferrous iron content of intravenous iron formulations

Ajay Gupta,Raymond D. Pratt,Alvin L. Crumbliss

DOI: https://doi.org/10.1007/s10534-016-9923-7

2016-03-08

BioMetals

Abstract:The observed biological differences in safety and efficacy of intravenous (IV) iron formulations are attributable to physicochemical differences. In addition to differences in carbohydrate shell, polarographic signatures due to ferric iron [Fe(III)] and ferrous iron [Fe(II)] differ among IV iron formulations. Intravenous iron contains Fe(II) and releases labile iron in the circulation. Fe(II) generates toxic free radicals and reactive oxygen species and binds to bacterial siderophores and other in vivo sequestering agents. To evaluate whether differences in Fe(II) content may account for some observed biological differences between IV iron formulations, samples from multiple lots of various IV iron formulations were dissolved in 12 M concentrated HCl to dissociate and release all iron and then diluted with water to achieve 0.1 M HCl concentration. Fe(II) was then directly measured using ferrozine reagent and ultraviolet spectroscopy at 562 nm. Total iron content was measured by adding an excess of ascorbic acid to reduce Fe(III) to Fe(II), and Fe(II) was then measured by ferrozine assay. The Fe(II) concentration as a proportion of total iron content [Fe(III) + Fe(II)] in different lots of IV iron formulations was as follows: iron gluconate, 1.4 and 1.8 %; ferumoxytol, 0.26 %; ferric carboxymaltose, 1.4 %; iron dextran, 0.8 %; and iron sucrose, 10.2, 15.5, and 11.0 % (average, 12.2 %). The average Fe(II) content in iron sucrose was, therefore, ≥7.5-fold higher than in the other IV iron formulations. Further studies are needed to investigate the relationship between Fe(II) content and increased risk of oxidative stress and infections with iron sucrose.

biochemistry & molecular biology
Application of validated UV-Vis spectrophotometry-colorimetric methods for specific quantification of deferiprone in the development of iron-responsive nanoparticle loaded into dissolving microneedle

Sitti Nur Khadijah Maharani,Muh Taufik Hidayat,Indianty Dwi Ramadhany,Nur Izzah Khairani,Nur Annisa Rahman,Andi Dian Permana

DOI: https://doi.org/10.1007/s00604-024-06661-1

2024-09-10

Abstract:Deferiprone (DFP) is one of the iron-chelating agents used in iron overload therapy for patients with ß-thalassemia major (ß-TM). However, the use of DFP is limited as it experiences a first-pass effect and can potentially cause iron deficiency due to uncontrolled release. Therefore, iron-responsive (NP-IR) DFP nanoparticle innovation was developed to control DFP release. A dissolving microneedle system (NP-IR-DMNs) was used to maximize DFP release. However, in support of this development, validation of analytical methods using spectrophotometry and colorimetrics was carried out. UV-Vis spectrophotometry is an approach that is easy to use, practical, and more cost-effective than others. The DFP levels were determined in normal and iron-overloaded medium solutions with 1%, 2%, and 4% concentrations. In addition, DFP levels were also measured in rat plasma using the colorimetric method with the addition of FeCl3 reagent to increase sensitivity for the detection of the analyte. The procedures used as guidelines in the validation procedure are The International Council for Harmonization (ICH). As a result, all linear correlation values of medium and plasma ≥ 0.999 were obtained. The LOQ levels obtained were 0.55 µg/mL, 0.44 µg/mL, 0.42 µg/mL, 0.52 µg/mL, and 1.01 µg/mL in plasma, 1% FeSO4, 2% FeSO4, 4% FeSO4, and normal media, respectively. The accuracy and precision were confirmed valid, as all values were within the requirements and did not change during dilution. Then, this approach was successfully applied to determine the levels of DFP in NP-IR integrated into DMNs.
Determination of Iron in Some Selected Iron Containing Tablets Using Redox Titration

Aliyu Zainab Folashade,Muhammad Auwal Balarabe

DOI: https://doi.org/10.11648/J.WJAC.20190403.13

2019-09-30

Abstract:Iron is an essential trace element, required for haemoglobin formation and the oxidative process of living tissues. A comparative study of the determination of iron in iron tablets was carried out using Redox titration on five samples of capsule containing iron. The capsules were analyzed using Redox titration on five of the samples containing iron content inform of ferrous fumarate. The weight of ferrous fumarate Fe (C4H2O4) as well as elemental Fe2+ in milligram per gram for each capsule containing ferrous fumarate was determined. The titration was carried out using potassium permanganate (vii) (KMNO4) which is the oxidation agent. The results obtained indicated Chemiron contained 144±4.61 (mg/g) while the label contained 150mg/g, Astyfer contained 74.6±5.69 (mg/g) while the label contained 80mg/g, Ferrobin plus contained 246±2.36 (mg/g) while the label contain 300mg/g, Emivite super contain 102±3.64 (mg/g) while the label contain 100mg/g, and Maxiron 265±1.73 (mg/g) while the label contain 250mg/g. Base on the results for the analysis of all the sample it can be concluded that Maxiron have the highest percentage of iron which is best supplements for adult lacking high percentage of iron. However, Astyfer has the lowest amount of iron which is the best supplement for infants who require very low amount of iron supplements.

Chemistry,Medicine
Total Iron Measurement in Human Serum With a Novel Smartphone-Based Assay

Michael Serhan,David Jackemeyer,Mindy Long,Mark Sprowls,Ismael Diez Perez,Wolfgang Maret,Fang Chen,Nongjian Tao,Erica Forzani

DOI: https://doi.org/10.1109/jtehm.2020.3005308

2020-01-01

IEEE Journal of Translational Engineering in Health and Medicine

Abstract:<span>Background: Abnormally low or high blood iron levels are common health conditions worldwide and can seriously affect an individual's overall well-being. A low-cost point-of-care technology that measures blood iron markers with a goal of both preventing and treating iron-related disorders represents a significant advancement in medical care delivery systems. Methods: A novel assay equipped with an accurate, storable, and robust dry sensor strip, as well as a smartphone mount and (iPhone) app is used to measure total iron in human serum. The sensor strip has a vertical flow design and is based on an optimized chemical reaction. The reaction strips iron ions from blood-transport proteins, reduces Fe(III) to Fe(II), and chelates Fe(II) with ferene, with the change indicated by a blue color on the strip. The smartphone mount is robust and controls the light source of the color reading App, which is calibrated to obtain output iron concentration results. The real serum samples are then used to assess iron concentrations from the new assay, and validated through intra-laboratory and inter-laboratory experiments. The intra-laboratory validation uses an optimized iron detection assay with multi-well plate spectrophotometry. The inter-laboratory validation method is performed in a commercial testing facility (LabCorp). Results: The novel assay with the dry sensor strip and smartphone mount, and App is seen to be sensitive to iron detection with a dynamic range of 50 – $300~mu text{g}$ /dL, sensitivity of 0.00049 a.u/ $mu text{g}$ /dL, coefficient of variation (CV) of 10.5%, and an estimated detection limit of $sim 15~mu text{g}$ /dL These analytical s-ecifications are useful for predicting iron deficiency and overloads. The optimized reference method has a sensitivity of 0.00093 a.u/ $mu text{g}$ /dL and CV of 2.2%. The correlation of serum iron concentrations (N = 20) between the optimized reference method and the novel assay renders a slope of 0.95, and a regression coefficient of 0.98, suggesting that the new assay is accurate. Last, a spectrophotometric study of the iron detection reaction kinetics is seen to reveal the reaction order for iron and chelating agent. Conclusion: The new assay is able to provide accurate results in intra- and inter- laboraty validations, and has promising features of both mobility and low-cost manufacturing suitable for global healthcare settings.</span>
Physicochemical and structural characterization of iron-sucrose formulations: a comparative study

Bhavesh S Barot,Punit B Parejiya,Dharmik M Mehta,Pragna K Shelat,Gaurang B Shah

DOI: https://doi.org/10.3109/10837450.2013.795171

Abstract:Intravenous polynuclear iron formulations are vital components in the treatment of iron deficiency anemia associated with chronic kidney disease as well as other diseases associated with gastro-intestinal and cardio-vascular system. Intravenous iron preparations consist of iron-carbohydrate nanoparticles with iron-oxyhydroxide as a core covered by carbohydrate shell. These preparations should be very well characterized in terms of their physicochemical properties and pharmacological profile in order to establish safety and efficacy. The present research work was aimed to physicochemically characterize a new generic iron-sucrose preparation (IS-Claris) and establish its equivalency with the reference product (Venofer®). Various analytical techniques including gel permeation chromatography (GPC), mass spectroscopy (MALDI-TOF), absorption spectroscopy, X-ray diffraction analysis (XRD), nuclear magnetic resonance spectroscopy (proton and (13)C NMR), Fourier transform infrared spectroscopy (FTIR) and thermal gravimetric analysis (TGA) were employed. It was observed that the specifications of IS-Claris obtained through these analyses reflect those of Venofer® and hence the two formulations were considered comparable.
Development of a Quantitative Determination Technique for Ascorbic Acid in Medicines

N. Sh. Kaisheva,A. Sh. Kaishev

DOI: https://doi.org/10.1007/s11094-023-03018-5

2024-01-17

Pharmaceutical Chemistry Journal

Abstract:A coordination compound of iron(III) ion with 1,10-phenanthroline, or the oxidized form of ferroin (OFF), which was obtained via the reaction of phenanthroline hydrochloride and iron(III) ammonium sulfate (3:1) in acidic solution and standardized by indirect iodometry, was proposed for use as a titrant for quantitative determination of ascorbic acid (AA) in drugs. The developed method for determining AAwas characterized by satisfactory validation indicators of specificity, linearity ( r = 0.990), extended analytical range (50 – 170% AA), accuracy (AA recovery 99.6%), precision (RSD 1.3%), and low relative error of determination (å 2.9%). The procedure for AA analysis using OFF did not depend on the solution pH and ionic strength and enabled titrations in colored and cloudy solutions. The technique was tested on various commercial drugs: 5% AAsolution for injection, Revit drops, AA tablets with glucose, and cinnamon rose hips.

pharmacology & pharmacy,chemistry, medicinal
Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products

Peng Zou,Katherine Tyner,Andre Raw,Sau Lee

DOI: https://doi.org/10.1208/s12248-017-0126-0

Abstract:Iron carbohydrate colloid drug products are intravenously administered to patients with chronic kidney disease for the treatment of iron deficiency anemia. Physicochemical characterization of iron colloids is critical to establish pharmaceutical equivalence between an innovator iron colloid product and generic version. The purpose of this review is to summarize literature-reported techniques for physicochemical characterization of iron carbohydrate colloid drug products. The mechanisms, reported testing results, and common technical pitfalls for individual characterization test are discussed. A better understanding of the physicochemical characterization techniques will facilitate generic iron carbohydrate colloid product development, accelerate products to market, and ensure iron carbohydrate colloid product quality.
Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation

Amy Barton Pai

DOI: https://doi.org/10.1111/nyas.13461

Abstract:Intravenous iron formulations are a class of complex drugs that are commonly used to treat a wide variety of disease states associated with iron deficiency and anemia. Venofer® (iron-sucrose) is one of the most frequently used formulations, with more than 90% of dialysis patients in the United States receiving this formulation. Emerging data from global markets outside the United States, where many iron-sucrose similars or copies are available, have shown that these formulations may have safety and efficacy profiles that differ from the reference listed drug. This may be attributable to uncharacterized differences in physicochemical characteristics and/or differences in labile iron release. As bioequivalence evaluation guidance evolves, clinicians should be educated on these potential clinical issues before a switch to the generic formulation is made in the clinical setting.
A new green method for indirect determination of ferric ions in biological samples using Ascorbic acid as reducing agent via the development of CFIA system

Bushra B. Qassim,Luma L. Hamed

DOI: https://doi.org/10.1088/1742-6596/1999/1/012145

2021-09-01

Journal of Physics: Conference Series

Abstract:Abstract A simple, sensitive, automated and environmentally friendly FI/MZ technique was suggested for the indirect determination of iron (III) as ferric chloride in bulk and biological. These method involve the reduction of Fe (III) to Fe (II) using ascorbic acid as reducing agent, the reduced ion was reacted with 1,10- phenanthroline as a selective organic reagent to form red-orange complex, measured at λ=510 nm. The complexation ratio between matel ion with ligand was 1:3 ratio (M: L). The colored product obeyed Beer’s Law with linear ranges 1-30 and 8-75 μg/mL with detection limits 1.02, 0.28 μg/mL for batch and FIA/MZ methods, respectively. The rate of sampling was 54 sample/h, the %RSD less than 2% and the recovery was about 99%. The developed technique was simply and low cost with high throughput, it provides the use of an aqueous medium as carrier of chemicals in flow system that is nontoxic and causes no pollution, thereby belonging to green chemistry. The proposed procedure can be successfully applied to estimate the content of Iron (III) in biological samples. The results of estimation are satisfactory as compared with those given by a reference method, showed the new method to be accurate and precise at the 95% confidence level.
Synthesis of New Dithiocarbamate Derivative Reagent for Micro Extraction and Determination of Iron(II) Ion in Aqueous Solution

Ivan Malik Shaker,Ahmed Fadhil Khudhair,Hayder Hamied Mihsen

DOI: https://doi.org/10.22146/ijc.87422

2024-08-01

Indonesian Journal of Chemistry

Abstract:The new reagent N-methyl-N-((((4-chlorophenyl)diazenyl)thio)carbonothioyl)aniline (L) was synthesized via the reaction of sodium N-methyl-N-phenyldithiocarbamate with 4-chlorobenzenediazonium salt. The reagent was identified with many techniques, such as CHNS elemental analysis, UV-vis spectroscopy, FTIR spectroscopy, mass spectroscopy, 1H-NMR, and 13C-NMR spectroscopy. The Fe(II) ion was utilized to create a metal complex by reacting 2 mol of reagent with 1 mol of iron(II) chloride. Two approaches that were utilized for M:L ratio determination are mole ratio and Job methods. All of these refer to the 1:2 ratio for the complex. The solid complex was prepared and identified with the previous techniques, and additional electrical molar conductivity, and magnetic susceptibility measurements. A tetrahedral structure for the prepared complex was suggested based on spectroscopic measurements and elemental analysis results. Cloud point extraction was created for the preconcentration and separation of Fe(II) in drug samples by forming a rich phase using Triton X-114 at 80 °C temperature and pH 5 measurements utilizing flame atomic absorption spectroscopy and UV-vis spectrophotometer at λmax 635 nm. The calibration curve of Fe(II) was linear in the extent of 0.2–1.0 μg/mL with r2 of 0.996. The detection limit and quantification are 0.0504 and 0.1530 μg/mL.
Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose

Susann Neiser,Daniel Rentsch,Urs Dippon,Andreas Kappler,Peter G. Weidler,Jörg Göttlicher,Ralph Steininger,Maria Wilhelm,Michaela Braitsch,Felix Funk,Erik Philipp,Susanna Burckhardt

DOI: https://doi.org/10.1007/s10534-015-9845-9

2015-03-24

BioMetals

Abstract:The advantage of the new generation IV iron preparations ferric carboxymaltose (FCM), ferumoxytol (FMX), and iron isomaltoside 1000 (IIM) is that they can be administered in relatively high doses in a short period of time. We investigated the physico-chemical properties of these preparations and compared them with those of the older preparations iron sucrose (IS), sodium ferric gluconate (SFG), and low molecular weight iron dextran (LMWID). Mössbauer spectroscopy, X-ray diffraction, and Fe K-edge X-ray absorption near edge structure spectroscopy indicated akaganeite structures (β-FeOOH) for the cores of FCM, IIM and IS, and a maghemite (γ-Fe2O3) structure for that of FMX. Nuclear magnetic resonance studies confirmed the structure of the carbohydrate of FMX as a reduced, carboxymethylated, low molecular weight dextran, and that of IIM as a reduced Dextran 1000. Polarography yielded significantly different fingerprints of the investigated compounds. Reductive degradation kinetics of FMX was faster than that of FCM and IIM, which is in contrast to the high stability of FMX towards acid degradation. The labile iron content, i.e. the amount of iron that is only weakly bound in the polynuclear iron core, was assessed by a qualitative test that confirmed decreasing labile iron contents in the order SFG ≈ IS > LMWID ≥ FMX ≈ IIM ≈ FCM. The presented data are a step forward in the characterization of these non-biological complex drugs, which is a prerequisite to understand their cellular uptake mechanisms and the relationship between the structure and physiological safety as well as efficacy of these complexes.

biochemistry & molecular biology
Dissimilar ferric derisomaltose formulations - In vitro comparisons between an originator and its intended similars

Peter Langguth,Reetesh Sharma,Sameer Tulpule,Martin Hansen,Michael Auerbach

DOI: https://doi.org/10.1016/j.ejpb.2024.114426

Abstract:Background: The complex nature of intravenous (IV) iron formulations makes manufacturing and characterising similars challenging. This study examined whether simple in vitro tests can distinguish the high-dose IV iron formulation, Monofer® (ferric derisomaltose [FDI]), from the first intended copies of FDI, Rapifer® (FDI intended similar A [FDIIS-A]) and Tosiron® (FDI intended similar B [FDIIS-B]), approved in India and Pakistan, respectively. Neither intended similar is available in Europe or the United States. Methods: Iron content, pH, density, non-volatile residue, carbohydrate content, molecular weight distribution, complex robustness (measured using acid hydrolysis half-life [t½]) and free (dialysable) iron content were examined. Mean results from three batches of FDIIS-A were compared with mean values calculated from three batches of Monofer®. Due to product withdrawal, only one batch of FDIIS-B was available for comparison with Monofer®. Results: Iron content was similar for all formulations (∼100 mg/mL). The chromatograms (obtained using gel permeation chromatography) of FDIIS-A and FDIIS-B differed from that of Monofer®. FDIIS-A was substantially less robust than Monofer® (t½: 15 h versus 40.3 h); t½ for FDIIS-B was not tested. Free iron content was substantially higher in FDIIS-A (0.091 % w/v) and FDIIS-B (1.0 % w/v) versus Monofer® (<0.003 % w/v). Where tested, remaining parameters varied between the formulations (insufficient sample quantities prevented all tests being conducted for all intended similars). For all tests, greater inter-batch variability was seen for FDIIS-A versus Monofer®. Conclusions: Simple in vitro tests demonstrated that, aside from total iron content, the first intended similars of FDI bear little resemblance to their originator drug. It is clear that the efficacy and safety profile of Monofer® cannot be extrapolated to the two intended similars. The results call for increased regulatory scrutiny of intended IV iron similars.
An Optimized Process for the Preparation of Aqueous Ferric Carboxymaltose: Synthesis and Structural Characterization

Ozra Tabasi,Mahdi Roohi Razlighi,Mohammad Ali Darbandi

DOI: https://doi.org/10.2174/2211738509666210114160941

Abstract:Background: Ferric carboxymaltose (FCM) formulation consists of iron-carbohydrate nanoparticles where iron-oxyhydroxide as a core is covered by a carbohydrate shell. The present work provides an improved synthesis process of FCM as an intravenous iron, active pharmaceutical ingredient. Methods: Water-soluble FCM complex was prepared from the reaction of ferric hydroxide precipitation with an aqueous solution of oxidized maltodextrin (MD) at optimum temperature and pH conditions. A systematic approach was followed to obtain the optimal weight ratio of the maltodextrin/ ferric chloride for FCM synthesis process with suitable-sized nanoparticles. Physical characterization of newly synthesized ferric carboxymaltose (FCM-NP) was performed to establish its equivalency with the reference product (Ferinject). Results: The size distribution of the whole nanoparticles determined by dynamic light scattering (DLS) was in the range of 15-40 nm with an average particle size of 26 ± 6.6 and 25.8 ± 4.9 for FCM-NP and Ferinject, respectively. X-ray diffraction (XRD) results of FCM-NP and Ferinject indicated the Akaganeite structure of iron-oxyhydroxide. The iron content of particles (cores) measured by Atomic absorption spectroscopy (AAS) was almost equal for the two formulations. The Fourier transform infrared (FTIR) spectra of Ferinject and FCM-NP were approximately similar. Conclusion: Various analytical methods, including FTIR spectroscopy, XRD analysis, DLS technique, TEM, and AAS were employed. It was observed that the specifications of FCM-NP obtained by these analyses were almost identical to those of Ferinject. Accordingly, the two formulations were considered comparable.
Indirect potentiometric titration of ascorbic acid in pharmaceutical preparations using copper based mercury film electrode

Meeran Mohideen Abdul Kamal Nazer,Abdul Rahman Shahul Hameed,Patel Riyazuddin

DOI: https://doi.org/10.1248/cpb.52.38

Abstract:A simple and rapid potentiometric method for the estimation of ascorbic acid in pharmaceutical dosage forms has been developed. The method is based on treating ascorbic acid with iodine and titration of the iodide produced equivalent to ascorbic acid with silver nitrate using Copper Based Mercury Film Electrode (CBMFE) as an indicator electrode. Interference study was carried to check possible interference of usual excipients and other vitamins. The precision and accuracy of the method was assessed by the application of lack-of-fit test and other statistical methods. The results of the proposed method and British Pharmacopoeia method were compared using F and t-statistical tests of significance.
Control Of The Iron State In Pharmaceuticals Used For Treatment And Prevention Of Iron Deficiency Using Mössbauer Spectroscopy

Irina V. Alenkina,Michael I. Oshtrakh

DOI: https://doi.org/10.1016/j.xphs.2024.02.023

IF: 3.8

2024-02-28

Journal of Pharmaceutical Sciences

Abstract:Various iron-containing medicaments, vitamins and dietary supplements are used or developed for treatment and prevention of the iron deficiency anemia which is very dangerous for human and may cause various disorders. From the other hand, blood losses, iron poor diet, microelements (co-factors) deficiency, metabolic failures, absorption problems, etc. can change the iron status and affect the health. These pharmaceuticals contain iron compounds in the ferrous and ferric states. It is known that ferrous salts are more suitable for the intestinal intake than ferric ones. On the other hand, pharmaceutically important ferritin analogues contain ferric hydrous oxides and appear to be effective for both injections and peroral administration. 57 Fe Mössbauer spectroscopy is a unique physical technique which allows one to study various iron-containing materials including pharmaceuticals. Therefore, this technique was applied to study iron-containing pharmaceuticals for the analysis of the iron state, identification of ferric and ferrous compounds, revealing some structural peculiarities and for detection of aging processes in relation to the iron compounds. This review considers the main results of a long experience in the study of iron-containing pharmaceuticals by Mössbauer spectroscopy with critical analysis that may be useful for pharmacists, biochemists, biophysicists, and physicians.

pharmacology & pharmacy,chemistry, medicinal, multidisciplinary

Lysophospholipid mediators of immunity and neoplasia.

A comprehensive study of intravenous iron-carbohydrate nanomedicines: From synthesis methodology to physicochemical and pharmaceutical characterization

Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations

An analytical method for the quantitative determination of iron ion chelating capacity: development and validation

ESI-MS quantitation of iron as its 4-(2-pyridylazo)resorcinol (PAR) complex: application to pharmaceutical tablets containing iron oxide pigment

A Friendly Complexing Agent for Spectrophotometric Determination of Total Iron

Ferrous iron content of intravenous iron formulations

Application of validated UV-Vis spectrophotometry-colorimetric methods for specific quantification of deferiprone in the development of iron-responsive nanoparticle loaded into dissolving microneedle

Determination of Iron in Some Selected Iron Containing Tablets Using Redox Titration

Total Iron Measurement in Human Serum With a Novel Smartphone-Based Assay

Physicochemical and structural characterization of iron-sucrose formulations: a comparative study

Development of a Quantitative Determination Technique for Ascorbic Acid in Medicines

Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products

Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation

A new green method for indirect determination of ferric ions in biological samples using Ascorbic acid as reducing agent via the development of CFIA system

Synthesis of New Dithiocarbamate Derivative Reagent for Micro Extraction and Determination of Iron(II) Ion in Aqueous Solution

Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose

Dissimilar ferric derisomaltose formulations - In vitro comparisons between an originator and its intended similars

An Optimized Process for the Preparation of Aqueous Ferric Carboxymaltose: Synthesis and Structural Characterization

Indirect potentiometric titration of ascorbic acid in pharmaceutical preparations using copper based mercury film electrode

Control Of The Iron State In Pharmaceuticals Used For Treatment And Prevention Of Iron Deficiency Using Mössbauer Spectroscopy